Cencora (COR) shifts to specialty pharma infrastructure, boosting margins via acquisitions and raising FY2026 EPS guidance.
Live sports are the last reliable exception, and the money knows it. A game cannot be paused, skipped, or spoiled without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results